Lhrh (Gonadorelin Acetate)

Gonadorelin acetate binds to GnRH receptors on the anterior pituitary, stimulating a rapid release of the gonadotropins luteinizing hormone (LH) and follicle‑stimulating hormone (FSH). The increased LH and FSH promote gonadal steroid production and support ovulation or enable hormonal assessment.

The dosage of Lhrh is determined by the prescribing clinician based on the specific indication, patient characteristics, and treatment protocol. Healthcare professionals set the exact amount, frequency, and duration of therapy.

Safety data for Lhrh during pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Lhrh, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Lhrh contains gonadorelin acetate, a short‑acting GnRH analogue, whereas many other GnRH agonists (e.g., leuprolide, triptorelin) are longer‑acting peptides. Short‑acting agents like Lhrh allow more precise, rapid control of LH/FSH release, which can be advantageous in diagnostic testing and certain assisted‑reproduction cycles.

Lhrh must be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The product should be kept in its original packaging until use to maintain stability and sterility.

Lhrh is supplied as an injectable solution for intravenous administration. It is typically given by a qualified healthcare professional under controlled conditions, with the exact injection volume and rate dictated by the prescribing protocol.

Serious risks include severe hypotension or syncope, anaphylactic reactions, and, rarely, pituitary apoplexy. Patients should be monitored closely for signs of cardiovascular compromise or allergic response during and after the injection.

Lhrh should be avoided in individuals with known hypersensitivity to gonadotropin‑releasing hormone analogues, in patients with active hormone‑dependent cancers unless specifically indicated, and in those for whom the diagnostic or therapeutic benefit does not outweigh potential risks, as determined by a physician.